00:56 Good afternoon and welcome to SI-BONE's Fourth Quarters’ Earnings Conference Call. At this time, all participants are in a listen-only mode. We'll be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. 01:16 I would now like to turn the call over to Matt Basco from the Gilmartin Group, for a few introductory comments.

01:24 Thank you for participating in today's call. Joining me are Laura Francis, Chief Executive Officer and Anshul Maheshwari, Chief Financial Officer. Earlier today, SI-BONE released financial results for the quarter ended December 31, 2021. A copy of the press release is available on the company's website. 01:40 Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. 02:02 These forward-looking statements are based on the company's current expectations and inherently involve risks and uncertainties. These risks include the impact the COVID-19 pandemic will have on the ability and desire of patients and physicians to undergo procedures using the company's products, the duration of the COVID-19 pandemic and whether the COVID-19 pandemic will recur in the future. 02:20 Other forward-looking statements include our examination of operating trends and our future financial expectations such as expectations for hiring, surgeon training and adoption active surgeons, new products, clinical trial enrollment and reimbursement decisions and are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. 02:45 Accordingly, you should not place undue reliance on these statements. For a list and the description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. SI-BONE disclaims any intention or obligation, except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time sensitive information and is accurate only as of the live broadcast today February 28, 2022. 3:17 And with that, I'll turn the call over to Laura.

03:20 Thanks, Matt. Good afternoon and thank you for joining us. For today's call, I will provide opening comments and the business update, followed by Anshul, who will provide additional detail regarding our financial results and initial 2022 guidance. 03:37 Let me start with our performance in the fourth quarter and full year 2021. I'm pleased with the team's execution in 2021 as we extended our market leadership position, grew our commercial infrastructure to a 150 U.S. sales representatives, expanded exclusive payor coverage to over 160 million U.S. covered lives and ended the year with a record 690-plus U.S. active surgeons. 04:03 Our revenue consistent with our pre-announcement on January 10 for the fourth quarter of 2021 was $25.2 million, representing growth of 14% compared to the fourth quarter of 2020. Despite various COVID surges throughout the year, we were able to generate sequential revenue growth for the third straight quarter. For the full year 2021, we generated revenue of $90.2 million, representing growth of 23% compared to full year 2020. We navigated through the pandemic very well due to consistent and focused commercial execution. 04:42 Now let me provide some insight into the impact of COVID-19 on our U.S. operations the fourth quarter and early 2022. Despite the impact of Delta and Omicron, growing demand for our solutions, allowed us to deliver sequential monthly revenue growth in the fourth quarter. Based on our booking records in the fourth quarter, approximately 100 cases which had been scheduled, were deferred due to COVID in the U.S. This impacted revenue in the fourth quarter by over $800,000. These are the cases that were booked and then postponed. But of course, there are many more cases that were affected by COVID. 05:22 We estimate that Omicron resulted in approximately 40 U.S. cases has…

12:49 Thanks, Laura. Good afternoon, everyone. Our fourth quarter total revenue was $25.2 million, representing growth of 14%, compared to the prior year period. U.S. revenue was $23.3 million, increasing 13% compared to the prior year period. International revenue was $1.9 million, increasing 28% compared to the prior year period. Even with the multiple surges in the quarter, resulting in approximately 100 case deferrals in the U.S., and pressure on Europe case volumes in December, we delivered steady sequential monthly growth in worldwide procedure volumes with December being the highest case volume month in company history, re-affirming the underlying momentum in the business. 13:40 Gross margin for the fourth quarter of 2021 was 87%, compared to 90% in the corresponding period in 2020. Gross margin in the fourth quarter was impacted by an increase in cost of operations to support the growth of the business. Operating expenses increased 29% to $35.8 million in the fourth quarter 2021 as compared to $27.7 million in the prior-year period. The increase was driven by higher sales and marketing costs related to increased sales hiring, higher travel costs, research and development expenses and increased stock-based compensation. 14:23 Our net loss was $14.5 million dollars or $0.43 per diluted share for the fourth quarter of 2021 as compared to a net loss of $9 million or $0.28 per diluted share in the prior year period. As of the end of the quarter, our cash and marketable securities were approximately $147 million and long-term borrowings were approximately $35 million. We believe we are well positioned from a liquidity standpoint to support our strategic priorities that will allow us to create long-term growth and shareholder value. 15:00 Moving to guidance. We are entering 2022 with several structural tailwinds including increasing underlying demand, a productive sales force, growing surgeon engagement, near-universal coverage in the U.S. and a growing portfolio of highly differentiated products. However, we remain cognizant of the unique external operating environment due to COVID-19 and its impact on elective procedures as well as health care infrastructure and staffing levels. 15:32 Our 2022 outlook is highly sensitive to assumptions on a steady global recovery which anticipates case scheduling and elective procedure levels normalizing throughout the year. For 2022, we expect annual revenue to range between $106 million to $108 million, representing year-over-year annual growth between 18% and 20%. The guidance reflects the assumed impact from Omicron variant in the first quarter of 2022, which we expect will result in mid to high-single digit revenue growth in the first quarter of 2022 when compared to the first quarter of 2021. 16:16 We expect the annual gross margin for 2022 to be in the mid to high 80% range. The annual gross margin range assumes a normal low-single digit ASP decline based on site of service mix and procedure mix at a higher depreciation of instrument trays based on our investments in 2021. 16:39 With that, I will turn the call over for questions. Operator?

16:42 Thank you. [Operator Instructions] The first question is from Craig Bijou with Bank of America. Your line is open.

17:06 Good afternoon. Thanks. Thanks for taking the questions and congrats on a pretty strong quarter.

17:15 Thanks, Craig.

17:18 We're maybe just talking about the sales reps and productivity with the reps and the thought process, for -- I believe you're not adding too many reps, if I have the numbers correct. Or you're not expecting to add too many reps in '22. So maybe just a little bit more understanding of your thought process there, the philosophy and how you see Rep productivity improving in '22.

17:51 Yeah. Thanks for the question and you're right, we are pretty pleased with our performance in the quarter and for the fiscal year and we like the sequential revenue growth, that we saw in the quarter. We like the fact that Q4 was a record quarter with sequential monthly growth on top of it and we think that we really did navigate quite well through a very difficult environment. I'm also really pleased that the team was able to hit their targets for the year in terms of number of sales reps, getting to that 150 people, dedicated sales force or 30% growth in territories. 18:37 So, going forward for 2022, we certainly have the opportunity to grow our productivity in terms of our sales team. So they're an important driver of our growth as we're penetrating our core market and expanding our presence in Trauma and Adult Deformity, especially with our second generation product coming online, during the first half of this year. We think that having a dedicated sales team has been a clear differentiator, especially in this unique COVID operating environment and did contribute to 25% procedure growth during the year. But it does help us to enter 2022 with a strong bench, that we should be able to leverage over time. 19:28 And so, we're currently targeting to end 2022 with 170 individuals in the sales force and then more than half of them are going to be quota-bearing territory managers. So, mid-teens increase from that particular perspective. But it really all comes to gaining that leverage on the existing sales force. We know that a Rep in a territory by himself or herself can do around $1.5 million of business. And then in a territory with the Rep Plus a clinical support specialist, they can do on average approximately $2 million of business. So the goal is to continue to add reps, but then start to see that leverage on our sales force as well in 2022.

20:22 Great. That's helpful, Laura. Thank you. And I do want to ask about expenses and how to think about expenses going forward. Obviously, there was a bit of an uptick this year but I know in the past you've made comments about getting back to normal spending levels.

20:42 Yeah.

20:41 It sounds like you might be able to get some leverage as you're not bringing on as many salespeople mix next year, but -- and maybe some of the R&D spending that you've done over the last couple of years will get some leverage out of there -- out of that also.

20:59 That's exactly...

20:57 I would love to...

21:02 I was saying, that's exactly right, Craig. And the investments that we've made from a sales perspective and an R&D perspective, we believe that 2022 is a year where we can start to gain leverage on those particular investments. So, our primary focus has been on revenue growth and capturing the opportunity that we have in the sacro-pelvic space, but we do also see 2022 as a year where we can gain leverage on that sales force and those R&D investments. And maybe Anshul can add a little bit more in terms of our thoughts there.

21:39 Yeah. Thanks, Laura. Hey, Craig. Good to talk to you. So when you think about OpEx growth rate, Craig, from our -- from the way we've modeled it, the OpEx growth rate is going to be a bit lower than the revenue growth rate. And like Laura said, it's going to be balancing between continued reinvestment in the business and the productivity gains. So that's what we're targeting. And when you think about the spend from a dollar perspective, it will increase for a few reasons. 22:09 One is, you just annualize the new hires that we did last year. Laura said, we grew our sales force by 30% last year, our TMs by 30% last year, you start annualizing some of the cost there. We will continue to invest in R&D even though we'll get leverage out of our existing portfolio but TORQ's a great example of when we've come up with a differentiated product. We've actually had a big impact on the market. So we feel good about that. And then we'll also be making some investments to scale our operating infrastructure, Craig, to be able to support the top-line growth that we're looking at over the next few years.

22:47 Great. Thanks for taking the questions. I'll hop back in the queue.

22:53 Thanks, Craig.

22:54 Thanks, Craig.

22:54 Thank you. Your next question comes from Kyle Rose with Canaccord. Your line is open.

23:00 Hi, everyone and congrats on the quarter. Wanted to see if we could just dig a little bit more into kind of Craig’s previous question just around productivity. I mean, I think you've provided that 1.5 million and that 2 million number for a few years now. When I just look at the backdrop -- I mean you've got much better reimbursement, you now have a product portfolio that's arguably three products when you include Trauma and Deformity versus just primary. I'm just trying to understand how we should really think about where those productivity gains from $1 million territory to a $2 million territory really comes from. And then if you could just help us quantify the impact of TORQ in 2021, when you think about the competitive gains versus moving in to Trauma -- more of a trauma focus in '22 would be helpful.

23:51 Thanks. Kyle. So, as I said, from a productivity perspective, we definitely have the opportunity to grow the average sales per Rep in the United States and it's -- given how important the sales team is to our revenue growth, it also can be regional in terms of the decisions that we're making. It's -- how large is a particular territory in terms of the number of surgeons or the size of the particular territory, how much travel is required in a particular territory, but we're getting to that point where we're big enough and we have enough coverage at this point in order to really focus a little bit more on sales productivity. So, we increased the number of sales reps this last year, and I'm talking about the senior territory managers by 30% over the last 12 months. 24:56 And so, what we're trying to do now is to get some leverage from those reps that we've added plus -- and it takes around 12 months to 18 months in order to get those reps productive. So let's be clear on that as well. But, the goal in 2022 is to moderate the number of adds that we have and to start really pushing that productivity. And so, the productivity comes from the senior sales Rep but it also comes from these junior clinical support specialists that we hired that are less expensive than the senior reps. So we're already thinking about ways in order to gain late -- leverage on the channel and so, our plan is to start gaining leverage in 2022 and beyond. So that's the answer to your first question. 25:51 Your second question on TORQ, we are not giving -- breaking out the specific revenues for TORQ, but I will tell you…

27:29 Great. Thank you. And then just one follow-up on my end is just -- I think you made a change or brought in a new marketing leader that really focusing around some of the direct-to-patient initiatives. I heard some of the commentary in the prepared remarks, just about seeing a doubling of the patients targeted. Could you just talk about how that translates into demand and the pull-through you've seen in the field?

27:55 There's a couple of key areas that we invested in, in the second half of 2021 as it relates to direct-to-patient. The first was just an increase in search spend because we had such a tight amount of search spend that the addition of spending actually showed very similar ROI on those additional dollars as the core dollars that we were spending previously. So our new VP of Digital Marketing really just started with the nuts and bolts of search. Driving patients to our website, having them complete the pain quiz, going through our Find-a-Doctor function and then ultimately being referred to surgeons. So -- and we are able to track all of that information and some of the metrics that we were mentioning are actually directly tied to those items that I just discussed. 28:55 In addition, in the fourth quarter, the team engaged in more direct-to-patient marketing, focusing on the lower part of the funnel using display advertising, using an educational type of campaign. And what I mean by the lower part of the funnel is those patients who have been in pain management with a chronic SI joint issue for an extended period of time. And so ultimately, these sorts of investments normally take around 12 months for us to actually see the impact from them, but as I said, we've already been making pretty significant investments during the second half of 2021, and so we would expect to see the impact directly turn into case development in the second half of 2022.

29:50 Your next question comes from David Rescott with Truist Securities. Your question please.

30:00 Hi, Laura. Thanks for taking the questions. First on the expanded reimbursement that you talked about in the prepared remarks. I mean, it's been a couple of months so far where -- or that's been in place and you've a couple of months so far this year already. But I guess, could you discuss if at all, whether it's anecdotal or more broadly, just where the impact of these factors have started to come out of the business. I mean is this opening up the door for new reps to re-engage with new accounts? Is it reactivating inactive physicians or just more utilization with them, some of the existing accounts? And then, how should we think about that impact throughout the year? Is that something that scales and starts to better impact the business in the second half of the year? Any color would be helpful.

30:43 Yeah, David. Thanks for the question. And we are really pleased with what we've seen from a reimbursement perspective. We finished 2021 with near-universal coverage of minimally invasive SI Joint Fusion and even more so with over 160 million patients who are exclusively covered for iFuse. So, we're really pleased with what we've seen there. In terms of the impact of some of those decisions, I think, in particular talking about Anthem and United, those exclusive -- so Anthem, first of all, was really one of the last payors to cover this procedure. They had a non-coverage procedure prior to August of 2021. And so, they finally moved to a positive coverage recommendation and that recommendation was exclusive to iFuse. So it was a huge win for us. 31:47 And then, a little bit surprising was the decision by UnitedHealthcare to switch from a positive general coverage decision to an exclusive decision. And so, in terms of what we're seeing right now, we're seeing these payors enforce the exclusive policy and while it's early days, we did see an uptick in Anthem case volumes in the fourth quarter that we do attribute to the Anthem decision. We do think that some of these early increases in Anthem cases are likely due to patients who are already in the system for some period of time. Certainly, some patients that had been denied coverage and then that coverage was overturned, it was appealed and there was a positive decision that was made. So that's what we believe that we're seeing here in these early days. 32:51 But I will say, we are quite excited about the potential tailwind for 2022 from the coverage decisions and the exclusives, especially in the case of Anthem since they were a non-coverage decision. So, in terms of what we would expect, it normally takes anywhere from six months to 12 months for a new case to work itself through the system before seeing a meaningful impact on volumes, but we have been really focused on the potential impact of these exclusives in our 2022 guidance. And -- so like I said, more of a six month to 12 month time frame in terms of impact.

33:36 Okay. That's helpful. I guess just -- you've derived some commenters around the canceled procedures and backlog of cases coming from Q4 and then into January and early February. I guess, what does the backlog look at -- like at this point. I know you mentioned there are some physicians that are scheduled out to three months or so [Technical Difficulty] but what does the current backlog look like? How is the pipeline of patients looking? And then how should we think about this -- or these patients progressing throughout the year? And how did you contemplate that within your guidance? Thank you.

34:11 Yeah. It's been an unusual period of time, obviously. We had delta in Q3, and then the start of Omicron in Q4 and then we did talk very openly about what we saw in January and February as well. And so what we've tried to do is to think about this contribution from these procedures over the next few months. And we're encouraged by the fact that we're seeing a decline in the deferrals between January and February. We don't know what March will necessarily look like. And in terms of backlog, the way that our system works is, we typically will see the scheduling of cases at the point in time where it's put on the books at a surgeon's office, so it's normally only a few weeks. But we do know anecdotally that there are significant backlogs in the three to four month range, as I had mentioned in my prepared remarks, from talking with some of our surgeons. 35:23 We also know that historically the way that this has worked, we've gone through so many surges at this point that, what typically happens is you'll have a surge, you'll see a lot of deferrals then you will see a decline then a stabilization and then the rescheduling of cases. And so the way that our guidance is looking at this right now is that January was a tough month, February a decline, the stabilization in March and then starting to see some of this rescheduling in the second quarter.

35:56 Okay. That's helpful. Thanks for taking the questions.

35:59 Thanks, David.

36:00 Thank you. Our next question is from David Saxon with Needham. Your question please.

36:08 Hi. Good afternoon, and thanks so much for taking the questions. I guess just one on -- '22 guidance implies 20% at the high end. But in the past, you've talked about being able to grow well into the 20% range. I think, Jeff once said, at 30% plus. So just wanted to hear your view on whether the lower implied growth reflects any change in contents and the opportunity in front of you, or if it's really just a tougher COVID impacted market, with perhaps some conservatism baked in.

36:48 Yeah. Thanks for the question, David and you're hinting in the right direction for us. We're really pleased with the execution in 2021. We actually had 25% growth in case volumes, even with multiple surges and it does reaffirm the growing demand for our procedure. We're in the strongest position in the history of the company with our universal coverage, 160 million patients covered exclusively, all of the surgeon engagement and the increase in the number of active surgeons are -- 30% increase in the number of territories in the United States with our sales team and then the growing portfolio of products. So we feel great about that too. But the operating environment was difficult in January. It's definitely improved in February with fewer deferrals and we believe that the healthcare environment is still progressing toward becoming fully normalized. 37:52 And so, when we think about procedure volumes continuing to grow month-over-month, we remain bullish on the underlying business momentum. But given the macro environment, we really think it's prudent to take a more conservative position around the pace of normalization and being deliberate on the impact of the tailwinds, including the exclusives, expansion into Trauma, our new product launch, all of those things on 2022 revenue growth. But I will reaffirm, we are extremely excited about the year 2022. We believe the underlying demand for our products remains robust and there is definitely upside, assuming a sustained recovery from Omicron and COVID more broadly. And that certainly could further accelerate growth in the second half of 2022 through higher surgeon productivity from a backlog in growth in our Trauma and Adult Deformity businesses.

38:49 The only thing I would add there, David, is you were spot on in the low end of our guidance. As Laura said, it assumes a very conservative scenario with some amount of impact from COVID throughout the year, including continued case deferrals and prolonged backlog of recapture rates. So similar to some of the disruptions we've seen over the last two years, which again if those on the side lines, we do believe there is tremendous upside in the second half of the year.

39:21 Got it. That's super helpful. And then just one on the exclusive policies. I was just wondering if you've seen any benefit with regards to surgeon training. And how are you messaging the exclusive coverage to docs that maybe were reluctant to engage in the past? Thanks so much for taking the questions.

39:45 Thanks, David. So as it regards the exclusive policies, at the point in time where the decisions were made by Anthem and UnitedHealthcare, we had a very major marketing campaign that worked with our field sales team in order to reach out to all of the surgeons who were impacted around the country by those decisions. And so, there was a first-round of very significant sales and marketing activities around the Anthem decision in the third quarter and then there were more activities that we engaged in, in the fourth quarter with UnitedHealthcare. And you're correct that it did give us the opportunity to re-engage with surgeons that we hadn't engaged with for a while. It allowed us to train some of those surgeons using the SImulator. It makes it very easy to reactivate surgeons who may have been trained previously or those that have expressed interest, but never gone through training. 40:53 And then it also even gave us the opportunity to talk about what's new within the business. So, we went in and there were some cases where it was appropriate to talk to the surgeons about our new TORQ product. There were cases where it made sense to talk about Bedrock and Adult deformity. And so, what our team was able to do was use the opportunity to speak with those surgeons once again, show them all of our clinical data, show them the five-year data that's driving a lot of these exclusive decisions and then talk to them about ways to engage with us. So it was a major focus point for the sales team along with our field marketing team and gave us a lot of opportunities for engagement in the second half of the year.

41:50 Great. Thanks, and congrats on the quarter.

41:51 Thanks, David.

41:54 Your next question comes from Drew Ranieri with Morgan Stanley. Your question please.

42:02 Hi, Laura and Anshul. Thanks for taking the questions. Just as we're thinking about 2022, can you maybe talk about some of the trends that you're seeing in your procedures moving to the ASC setting. I mean, are you seeing more of a -- or are you expecting more of a shift in the current operating environment? But -- I'll stop there. And I have a follow-up.

42:25 Yeah. The ASC environment has been a really important site-of-service for us over the last couple of years. So, as I stated in my prepared remarks, approximately 80% of our procedures are either hospital outpatient procedures or ASC procedures. And before the pandemic that number was in the single-digit range, we now have gotten in the -- in certain months and quarters into the 20% to 25% range for ASC sales. We do see the ASC is a long-term growth opportunity for us just because a lot of procedures are shifting to that site-of-service. It is cost-effective location for service and it's appealing for quite a few different reasons that also has been absolutely critical to our business over the last two years with the pandemic during surges, if hospitals were not able to perform procedures. So I'm not sure how much business we're going to see in the ASC setting, that has yet to be stated. 43:39 I originally thought that around 25% was going to be getting toward a maximum for us and I simplistically did that by thinking 50% of our surgeons are employed by hospitals, the other 50% are private practice and simplistically said those in private practice -- half of them may do procedures and ASCs, but that's changed. There are more of the private practice surgeons that want to do business in ASCs and in fact, a lot of the hospitals are actually developing relationships with ASCs and are shifting business there as well. So I think it's a long-term growth opportunity for the business.

44:28 Got it. Understood. And then just to shift gears to gross margins, but you made some comments about the quarter but I'd like to better understand your guidance for 2022 and some of the pieces there and whether or not kind of the inflationary cost environment is really being a factor in the gross margin guidance. And is 85% -- is this range the right go forward SI-BONE gross margin rate? Thank you.

44:59 Hey, Drew. Thanks a lot for that question. We obviously are really proud of our industry-leading gross margins and we came in for 2021 at about 88%. So, when you think about our guidance, both in 2022 and as we think longer term, the way we model it here is we've got a few levers that we look at. One is, the ASP decline that we tend to price in on a per procedure basis is not a per implant basis. And a lot of that is driven by site-of-service mix, like Laura said, more procedures in ASC, they tend to be a little bit more price sensitive. Especially if you see contribution from TORQ in Adult Deformity, which tend to use fewer implants than the primary SI Joint Fusion. So you've got some of that ASP pressure that we tend to model in and then we look into two other aspects. 45:56 The second one being the depreciation expense, especially as we expand our product portfolio, we're expanding the amount of instrument trays that are in the field. That depreciation flows through our gross margin. So that will put some pressure on it. And then when you think about inflation as well, we do model in some amount of inflation, especially this year, given everything that's going on, even though our supply chain team has done a phenomenal job in managing through the cost element and actually been very forward looking in terms of the demand trends and what we need. We do model that in. Now, where do you see long-term gross margin? Sort of that mid to potentially high 80s is where we look at. We're not going to be able to say is at 85%, but our aim is to keep it above that 85 number.

46:46 Our next question comes from Dave Turkaly with JMP Securities. Your line is open.

46:59 Great. Thanks. Well, I think I heard you say that the re-engaged surgeons -- that maybe some of the new products were helping with that. But of the 690 active, do you comment at all at how many of them were re-engaged guys versus let's say, brand new customers?

47:16 We don't comment on it but it definitely has been a focal area for us to re-engage surgeons. There was a pretty major push in the second half of 2022 to speak with surgeons who had previously been trained and...

47:38 Second half of '21.

47:39 In the second half of 2021, yeah.

47:41 Right.

47:42 And we'll continue to do that going forward as well. As we said, there were 1,800 surgeons who have trained and treated at least one patient and a thousand of them approximately did at least one procedure in all of 2021. So what that means is, there are approximately 800 surgeons who did not engage with us in that 12-month period, and so those continue to be target for us.

48:12 Got it. Thanks a lot.

48:15 Thanks, Dave.

48:17 Thank you. And this ends our Q&A session, I will pass it to -- back to Laura Francis for her final remarks.

48:25 Thanks so much, Carmen. I'm pleased with the team's execution in 2021. We hit several record milestones and as we look beyond the near-term impact from the recent resurgence of COVID-19, including the pressure on hospital infrastructure, we see strong underlying momentum in our business. In 2022, we'll continue to leverage our investments, to expand the market for sacro-pelvic surgical solutions and drive strong top line growth. I want to thank you for joining us today and I look forward to meeting you at upcoming investor conferences and events. Goodbye.

49:03 And with that, ladies and gentlemen, we thank you for participating in today's program. You may now disconnect. Have a wonderful day.